Print this page
-
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase III, Open-Label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer.
Protocol: 042316Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer.
Protocol: 042403Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease.
Protocol: 042404Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.
Protocol: 042405Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Dose Finding Study of CycloSam® (153Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewings Sarcoma, and other solid tumor(s) to the bone all eligible).
Protocol: 052201Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site
Breast
Lung
Prostate -
The Women's Circle of Health Study.
Protocol: 130404Principal Investigator:
-
Elisa V Bandera
Applicable Disease Sites: Breast - Female -
Adapting and Implementing Evidence-Based Breast Cancer Follow-up in Primary Care.
Protocol: 132103Principal Investigator:
-
Shawna Hudson
Applicable Disease Sites: Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Applicable Disease Sites: Breast
-
Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST).
Protocol: 132307Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Other Female Genital
Ovary
Pancreas
Prostate -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach
- 1
- 2